Systematic Reviews
Copyright ©The Author(s) 2024.
World J Meta-Anal. Dec 18, 2024; 12(4): 96981
Published online Dec 18, 2024. doi: 10.13105/wjma.v12.i4.96981
Table 3 Results of the Tampa Scale of Kinesiophobia scale of the studies
Ref.
Baseline MV (SD)
Intermediate measurement, MV (SD)
End of intervention, MV (SD)
Follow-up, MV (SD)
P value, baseline-finish
P value, baseline–follow up
Akodu et al[29], 2021 CSPSE: 40.17 ± 3.16
PE: 40.82 ± 2.44
DIE: 39.73 ± 2.28
4th week
CSPSE: 37.38 ± 3.20
PE: 39.46 ± 1.85
DIE: 39.79 ± 2.19
8th week
CSPSE: 33.17 ± 3.27
PE: 37.27 ± 1.95
DIE: 38.36 ± 3.36
-P = 0.072
P = 0.001
-
Cruz-Díaz et al[16], 2018 Mean value
PG: 34.50
CG: 34.00
6 th week
Mean value
PG: 27.50
CG: 33.00
12 th week
Mean value
PG: 27.50
CG: 32.50
-P < 0.001-
Cruz-Díaz et al[30], 2017 PMG: 34.52 ± 4.14
PEG: 36.50 ± 3.92
CG: 33.90 ± 4.23
6th week
PMG: 32.23 ± 3.06
PEG: 34.08 ± 4.1
CG: 34.26 ± 3.96
12th week
PMG: 31.73 ± 3.24
PEG: 32.00 ± 3.56
CG: 34.10 ± 4.04
-P < 0.05-
da Luz et al[31], 2014 PMG: 39.7 ± 8.1
PEG: 39.6 ± 8.0
-6th week
PMG: 35.3 ± 6.6
PEG: 34.1 ± 7.8
6th month
PMG: 40.0 ± 9.9
PEG: 34.9 ± 7.9
P > 0.05P < 0.001
Miyamoto et al[32], 2013 PG: 39.4 ± 6.1
CG: 39.5 ± 7.1
-6th week
PG: 36.3 ± 7.4
CG: 38.1 ± 8.3
6 th month
PG: 38.1 ± 7.2
CG: 38.9 ± 7.3
P = 0.20P = 0.61